Literature DB >> 15293556

Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product.

Kazushi Sakurai1, Hiroyuki Sasabe, Toshihisa Koga, Tetsuya Konishi.   

Abstract

Rebamipide, an antiulcer agent, is known as a potent hydroxyl radical (*OH) scavenger. In the present study, we further characterized the scavenging effect of rebamipide against *OH generated by ultraviolet (UV) irradiation of hydrogen peroxide (H2O2), and identified the reaction products to elucidate the mechanism of the reaction. Scavenging effect of rebamipide was accessed by ESR using DMPO as a *OH-trapping agent after UVB exposure (305 nm) to H2O2 for 1 min in the presence of rebamipide. The signal intensity of *OH adduct of DMPO (DMPO-OH) was markedly reduced by rebamipide in a concentration-dependent fashion as well as by dimethyl sulfoxide and glutathione as reference radical scavengers. Their second order rate constant values were 5.62 x 10(10), 8.16 x 10(9) and 1.65 x 10(10) M(-1) s(-1), respectively. As the rebamipide absorption spectrum disappeared during the reaction, a new spectrum grew due to generation of rather specific reaction product. The reaction product was characterized by LC-MS/MS and NMR measurements. Finally, a hydroxylated rebamipide at the 3-position of the 2(1H)-quinolinone nucleus was newly identified as the major product exclusively formed in the reaction between rebamipide and the *OH generated by UVB/H2O2. Specific formation of this product explained the molecular characteristics of rebamipide as a potential *OH scavenger.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293556     DOI: 10.1080/1071576042000209808

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  16 in total

1.  Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy.

Authors:  Shunji Fujimori; Yoko Takahashi; Katya Gudis; Tsuguhiko Seo; Akihito Ehara; Tsuyoshi Kobayashi; Keigo Mitsui; Masaoki Yonezawa; Shu Tanaka; Atsushi Tatsuguchi; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2010-10-06       Impact factor: 7.527

2.  Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.

Authors:  Lien Ngo; Hee-Doo Yoo; Phuong Tran; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-18       Impact factor: 2.745

3.  Rebamipide reduces recurrence of experimental gastric ulcers: role of free radicals and neutrophils.

Authors:  Kazushi Sakurai; Toshihiro Osaka; Katsuya Yamasaki
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

4.  Rebamipide, a gastro-protective drug, inhibits indomethacin-induced apoptosis in cultured rat gastric mucosal cells: association with the inhibition of growth arrest and DNA damage-induced 45 alpha expression.

Authors:  Yuji Naito; Hirokazu Kajikawa; Katsura Mizushima; Makoto Shimozawa; Masaaki Kuroda; Kazuhiro Katada; Tomohisa Takagi; Osamu Handa; Satoshi Kokura; Hiroshi Ichikawa; Norimasa Yoshida; Hirofumi Matsui; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

5.  Direct assessment of the antioxidant properties of midazolam by electron spin resonance spectroscopy.

Authors:  Mitsuuru Hata; Kyo Kobayashi; Fumihiko Yoshino; Ayaka Yoshida; Shuta Sugiyama; Chihiro Miyamoto; Fumiaki Tokutomi; Yojiro Maehata; Satoko Wada-Takahashi; Shun-Suke Takahashi; Tomoko Komatsu; Kazu-Ichi Yoshida; Masaichi-Chang-Il Lee
Journal:  J Anesth       Date:  2011-06-18       Impact factor: 2.078

6.  Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole.

Authors:  Norimasa Yoshida; Kazuhiro Kamada; Naoya Tomatsuri; Takahiro Suzuki; Tomohisa Takagi; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2010-03-03       Impact factor: 3.199

Review 7.  Small bowel injury in low-dose aspirin users.

Authors:  Hiroki Endo; Eiji Sakai; Takayuki Kato; Shotaro Umezawa; Takuma Higurashi; Hidenori Ohkubo; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2014-12-14       Impact factor: 7.527

8.  Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study.

Authors:  Yiqi Du; Zhaoshen Li; Xianbao Zhan; Jie Chen; Jun Gao; Yanfang Gong; Jianlin Ren; Liping He; Zhijian Zhang; Xiaozhong Guo; Jianshen Wu; Zibin Tian; Ruihua Shi; Bo Jiang; Dianchun Fang; Youming Li
Journal:  Dig Dis Sci       Date:  2008-02-21       Impact factor: 3.199

9.  Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study.

Authors:  Xue Han; Kui Jiang; Bangmao Wang; Lu Zhou; Xin Chen; Shu Li
Journal:  Clin Drug Investig       Date:  2015-10       Impact factor: 2.859

10.  Rebamipide enema therapy for left-sided ischemic colitis patients accompanied by ulcers: open label study.

Authors:  Satohiro Matsumoto; Kenichiro Tsuji; Satoshi Shirahama
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.